Allergy Therapeutics plc
AGY.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | £55 | £55 | £60 | £73 |
| % Growth | -0.3% | -7.4% | -18.1% | – |
| Cost of Goods Sold | £30 | £25 | £27 | £24 |
| Gross Profit | £25 | £30 | £33 | £49 |
| % Margin | 45.7% | 53.9% | 54.9% | 67.3% |
| R&D Expenses | £15 | £23 | £20 | £16 |
| G&A Expenses | £19 | £23 | £25 | £21 |
| SG&A Expenses | £38 | £42 | £49 | £47 |
| Sales & Mktg Exp. | £19 | £20 | £24 | £26 |
| Other Operating Expenses | £1 | -£0 | £4 | -£1 |
| Operating Expenses | £55 | £65 | £73 | £62 |
| Operating Income | -£30 | -£35 | -£35 | -£13 |
| % Margin | -53.6% | -63.9% | -58.5% | -17.9% |
| Other Income/Exp. Net | -£11 | -£4 | -£8 | -£0 |
| Pre-Tax Income | -£40 | -£39 | -£43 | -£13 |
| Tax Expense | -£0 | £1 | £1 | £1 |
| Net Income | -£40 | -£40 | -£43 | -£14 |
| % Margin | -72.9% | -72.9% | -72.3% | -18.9% |
| EPS | -0.008 | -0.011 | -0.064 | -0.021 |
| % Growth | 21.5% | 83.4% | -200.5% | – |
| EPS Diluted | -0.008 | -0.011 | -0.064 | -0.021 |
| Weighted Avg Shares Out | 4,766 | 3,743 | 670 | 643 |
| Weighted Avg Shares Out Dil | 4,766 | 3,743 | 670 | 643 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £7 | £4 | £2 | £1 |
| Depreciation & Amortization | £4 | £4 | £4 | £4 |
| EBITDA | -£29 | -£31 | -£36 | -£9 |
| % Margin | -53.5% | -55.7% | -60.8% | -11.9% |